TFE3-REARRANGED RENAL CELL CARCINOMA
Clinical trials for TFE3-REARRANGED RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new TFE3-REARRANGED RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for TFE3-REARRANGED RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise for rare kidney cancers
Disease control OngoingThis study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 participants will receive the drugs until their disease gets worse or side effects become too severe. The goal is …
Matched conditions: TFE3-REARRANGED RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hao Zeng • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …
Matched conditions: TFE3-REARRANGED RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC